JAMDA
June 13, 2017
Showing 101 - 110 of 113 results
JAMDA
April 18, 2017
Antipsychotics and the Risk of Cerebrovascular Accident: A Systematic Review and Meta-Analysis of Observational Studies
Studies investigating the association between antipsychotic use and the risk of cerebrovascular accident (CVA) showed inconsistent results.
JAMDA
June 8, 2016
Effect of a Proton Pump Inhibitor Deprescribing Guideline on Drug Usage and Costs in Long-Term Care
To assess the effect of a proton pump inhibitor (PPI) deprescribing guideline on PPI usage and PPI drug costs in one long-term care home in Ontario, Canada.
JAMDA
May 6, 2016
Impact of a Videoconference Educational Intervention on Physical Restraint and Antipsychotic Use in Nursing Homes: Results From the ECHO-AGE Pilot Study
US nursing homes care for increasing numbers of residents with dementia and associated behavioral problems. They often lack access to specialized clinical expertise relevant to managing these problems. Project ECHO-AGE provides this expertise through videoconference sessions between frontline nursing home ...
JAMDA
February 27, 2016
Antipsychotic Drug Use Is Not Associated With Long-Term Mortality Risk in Norwegian Nursing Home Patients
To assess the long-term mortality risk associated with antipsychotic drug (AP) use in nursing homes.
JAMDA
January 5, 2016
Physical Restraint and Antipsychotic Medication Use Among Nursing Home Residents With Dementia
To explore antipsychotic (AP) medications and physical restraint use and their effects on physical function and cognition in older nursing home residents.
JAMDA
December 20, 2015
Predictors of Functional Changes in Italian Nursing Home Residents: The U.L.I.S.S.E. Study
To identify independent predictors of the risk of functional decline in older nursing home (NH) residents.
JAMDA
July 31, 2015
Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis
To establish the mortality risk and adverse events associated with the use of atypical antipsychotic medications in people with Parkinson disease psychosis (PDP) in a clinically defined trial cohort.
JAMDA
December 15, 2014
A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People With Alzheimer's Disease (MAIN-AD)
Neuropsychiatric symptoms in Alzheimer disease (AD) cause significant distress and present a complex clinical challenge for treatment. Pharmacological treatment options are limited to antipsychotics, which carry extensive safety issues. There is emerging evidence to support the potential benefits of memant...
JAMDA
September 24, 2014
Use of Antipsychotic Drugs Among Residents With Dementia in European Long-Term Care Facilities: Results From the SHELTER Study
Behavioral and psychological symptoms of dementia (BPSD) are common reasons for use of antipsychotic drugs among older individuals with dementia. These drugs are not approved for such use and both the Food and Drug Administration and European Medicines Agency have issued warnings to limit such use.
